克隆性造血与急性缺血性卒中结局
研究纳入380例急性缺血性卒中患者和446例年龄匹配健康对照,采用靶向二代测序检测25个血液肿瘤常见突变基因,发现卒中患者CHIP患病率显著高于对照,且CHIP与卒中严重程度、出血转化和90天功能残疾独立相关。
要点
- 急性缺血性卒中患者CHIP患病率29.0%,高于健康对照的22.0%(p=0.024)。
- PPM1D突变与发生急性缺血性卒中最显著相关(aOR=7.85,95%CI=1.83-33.63,p=0.006)。
- CHIP与出血转化(aOR=5.63)和90天功能残疾(aOR=2.15)独立相关。
核心结论
- CHIP与发生急性缺血性卒中显著相关,PPM1D、TET2和DNMT3A序列变异是急性缺血性卒中的新预后因素。
研究设计与样本
- 前瞻性登记研究结合DNA样本库,纳入380例急性缺血性卒中患者和446例年龄匹配健康对照,对25个血液肿瘤常见突变基因进行靶向二代测序。
主要发现
- 急性缺血性卒中患者CHIP患病率为29.0%,健康对照为22.0%(变异等位基因频率1.5%,p=0.024)。
- PPM1D与发生急性缺血性卒中关联最显著(aOR=7.85,95%CI=1.83-33.63,p=0.006)。
- CHIP与初始NIHSS评分显著相关(β=1.67,p=0.022)。
- CHIP与出血转化独立相关:CH+组65/110 vs CH-组56/270(aOR=5.63,95%CI=3.24-9.77,p<0.001)。
- CHIP与90天功能残疾独立相关:CH+组72/110 vs CH-组99/270(aOR=2.15,95%CI=1.20-3.88,p=0.011)。
关键数值与推荐
- CHIP定义为变异等位基因频率1.5%的克隆性造血。
- 急性缺血性卒中患者CHIP患病率29.0% vs 健康对照22.0%(p=0.024)。
- PPM1D突变与急性缺血性卒中的aOR=7.85(95%CI=1.83-33.63,p=0.006)。
- CHIP与出血转化的aOR=5.63(95%CI=3.24-9.77,p<0.001)。
- CHIP与90天功能残疾的aOR=2.15(95%CI=1.20-3.88,p=0.011)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The effect of clonal hematopoiesis of indeterminate potential (CHIP) on the manifestation and clinical outcomes of acute ischemic stroke (AIS) has not been fully elucidated. METHODS: Patients with AIS were included from a prospective registry coupled with a DNA repository. Targeted next-generation sequencing on 25 genes that are frequently mutated in hematologic neoplasms was performed. The prevalence of CHIP was compared between patients with AIS and age-matched healthy individuals. A multivariate linear or logistic regression model was used to assess the association among CHIP and stroke severity, hemorrhagic transformation, and functional outcome at 90 days. RESULTS: In total, 380 patients with AIS (mean age = 67.2 ± 12.7 years; 41.3% women) and 446 age-matched controls (mean age = 67.2 ± 8.7 years; 31.4% women) were analyzed. The prevalence of CHIP was significantly higher in patients with AIS than in the healthy controls (29.0 vs 22.0%, with variant allele frequencies of 1.5%, p = 0.024). PPM1D was found to be most significantly associated with incident AIS (adjusted odds ratio [aOR] = 7.85, 95% confidence interval [CI] = 1.83-33.63, p = 0.006). The presence of CHIP was significantly associated with the initial National Institutes of Health Stroke Scale (NIHSS) score (β = 1.67, p = 0.022). Furthermore, CHIP was independently associated with the occurrence of hemorrhagic transformation (65/110 clonal hematopoiesis positive [CH+] vs 56/270 CH negative [CH-], aOR = 5.63, 95% CI = 3.24-9.77, p < 0.001) and 90-day functional disability (72/110 [CH+] vs 99/270 [CH-], aOR = 2.15, 95% CI = 1.20-3.88, p = 0.011). INTERPRETATION: CH was significantly associated with incident AIS. Moreover, particularly, sequence variations in PPM1D, TET2, and DNMT3A represent a new prognostic factor for AIS. ANN NEUROL 2023;94:836-847.
引用
- Lee EJ, An HY, Lim J, et al. Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes. Ann Neurol. 2023. PMID: 37532684. doi:10.1002/ana.26754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。